Royalty Pharma Plc Form 8-K Summary
Business Context and Reporting Period
Royalty Pharma Plc (RPRX) filed a Current Report on Form 8-K dated May 22, 2026. The filing reports the entry into a new material definitive agreement regarding the company's debt financing structure.
Key Financial Metrics and Debt Structure
The company entered into a new Revolving Credit Agreement with Bank of America, N.A., as Administrative Agent. Key terms include:
- Facility Size: $1.8 billion unsecured revolving credit facility.
- Maturity Date: May 22, 2031.
- Interest Rate: Based on Base Rate (Prime, Fed Funds + 0.5%, or Term SOFR + 1%) or Daily SOFR/Alternative Currency rates, plus an applicable margin.
- Commitment Fee: Applicable on the unused portion of the facility based on a pricing grid.
- Guarantors: Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC.
Material Changes Versus Prior Period
The new Credit Agreement refinanced and replaced in its entirety the Existing Credit Agreement dated September 15, 2021. Upon effectiveness of the new agreement, all obligations under the prior agreement were repaid, and all commitments were terminated in full.
Covenants, Risks, and Management Commentary
The new agreement imposes specific financial covenants and limitations on corporate activities:
- Consolidated Leverage Ratio: Must be maintained at or below 4.00 to 1.00 (or 4.50 to 1.00 following a qualifying material acquisition) of funded debt to Adjusted EBITDA.
- Consolidated Portfolio Cash Flow Ratio: Must be maintained at or below 5.00 to 1.00 (or 5.50 to 1.00 following a qualifying material acquisition).
- Consolidated Coverage Ratio: Must be maintained at or above 2.50 to 1.00 of Adjusted EBITDA to consolidated interest expense.
- Restrictive Covenants: Limits on non-obligor indebtedness, incurrence of liens, and consummation of certain merger or fundamental change transactions.
The filing text does not provide specific values for current revenue, profit, cash flow, or liquidity positions outside of the new debt facility terms.
Investor Verification Checklist
- Verify the full text of the Revolving Credit Agreement attached as Exhibit 10.1 for detailed definitions of Adjusted EBITDA and other financial metrics.
- Confirm the current funded debt levels to assess compliance with the new 4.00x leverage covenant.
- Review the pricing grid for the commitment fee to understand the cost of unused capacity.
- Monitor future filings for any amendments related to the "qualifying material acquisition" thresholds which allow for higher leverage ratios.